Avinger has reported that it will present the CONNECT II clinical trial results at the Vascular Interventional Advances (VIVA) conference being held in Las Vegas, Nevada, US, between 9-12 October 2012.
The prospective, multi-center, non-randomized trial has enrolled 100 peripheral artery disease (PAD) patients with femoropopliteal CTO lesions to study the safety and efficacy of interventional chronic total occlusion crossing Ocelot catheter.
By using real-time intravascular imaging optical coherence tomography, Ocleot allows physicians to see and navigate inside totally blocked arteries in the legs of patients suffering from PAD.
The company said the final results will be revealed by Matt Selmon, an interventional cardiologist of Heart Hospital of Austin and CONNECT II co-principal investigator.
According to the American Heart Association journal Circulation, PAD has been observed more in women than men.
